Australian experience shows high DAA uptake and rapid fall in rates of HCV viraemia among people who inject drugs
Michael Carter
Published: 28 November 2018
Providing hepatitis C virus (HCV) therapy with direct-acting antivirals (DAAs) to people who inject drugs can achieve rapid reductions in community prevalence of viraemia, according to Australian research published in the Journal of Hepatology. Uptake of HCV treatment increased from 10% to 41% after unrestricted access to DAAs was rolled out in March 2016, and the proportion of viraemic patients fell from 43% to 25%.
The authors believe their findings have significance for the World Health Organization (WHO) target of eliminating HCV as a public health threat by 2030.
Read More:
No comments:
Post a Comment